AZAYA THERAPEUTICS
Azaya Therapeutics is a San Antonio- based biotechnology company developing therapies for cancer and other serious medical conditions. In February 2017, the company was acquired by [Cytori Therapeutics](/organization/cytori-therapeutics).
AZAYA THERAPEUTICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2002-01-01
Address:
San Antonio, Texas, United States
Country:
United States
Website Url:
http://www.azayatherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
12103416600
Technology used in webpage:
Amazon Amazon Virginia Region NameBright
Similar Organizations
Affini-T Therapeutics
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.
Akan Biosciences
Akan Biosciences is a biotechnology and cellular therapy company developing next-generation injectable products.
GlycoT Therapeutics
GlycoT Therapeutics applies glycosylation technology for producing enzymes, oligosaccharides, glycopeptides and other glycoprotein products.
IntraLuminal Therapeutics
IntraLuminal Therapeutics provides products for interventional cardiologists and radiologists to recanalize totally occluded arteries.
NovelMed Therapeutics
NovelMed Therapeutics is a biotechnology company developing novel therapies for orphan and non-orphan diseases.
Seed Therapeutics
Seed Therapeutics is a biotech company that focuses on harnessing and engineering molecules.
Synthis Therapeutics
Synthis is an early-stage biotech company developing a therapeutic platform that rescues immune function.
Current Employees Featured
Founder
Official Site Inspections
http://www.azayatherapeutics.com
- Host name: ec2-52-71-57-184.compute-1.amazonaws.com
- IP address: 52.71.57.184
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Azaya Therapeutics"
Azaya Therapeutics Company Profile 2024: Valuation, …
Azaya Therapeutics is headquartered in San Antonio, TX. What is the size of Azaya Therapeutics? Azaya Therapeutics has 11 total employees. What industry is Azaya Therapeutics in? Azaya Therapeutics’s primary industry is …See details»
Azaya Therapeutics Inc - Company Profile and News
Company profile page for Azaya Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Azaya Therapeutics - Ownership and Business Overview - Mergr
Jan 16, 2017 Azaya Therapeutics was founded in 2002. Life Science M&A Summary in 2017. Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2017. The …See details»
Azaya Therapeutics (Proprietary Nanoparticle Development …
The current revenue for Azaya Therapeutics (Proprietary Nanoparticle Development Platform) is (). Who are Azaya Therapeutics (Proprietary Nanoparticle Development Platform)’s investors? …See details»
Azaya Therapeutics - Contacts, Employees, Board Members
Organization. Azaya Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. Azaya …See details»
Azaya Therapeutics, Inc. Elects Ze’ev Shaked, Ph.D., to Board of …
Azaya Therapeutics, Inc. today announced the election of Dr. Ze'ev Shaked to its Board of Directors. Dr. Shaked has extensive managerial and pharmaceutical product development …See details»
Azaya Therapeutics - Products, Competitors, Financials, Employees ...
Dec 18, 2017 Azaya Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 08112017 Prices from USD $250. Dec 18, 2017. Summary Azaya …See details»
ATI-1150 - Drug Targets, Indications, Patents - Synapse
ATI-1150: a TOP1 inhibitors Drug, Initially developed by Azaya Therapeutics, Inc., Now, its global highest R&D status is Pending, Mechanism: TOP1 inhibitors(DNA topoisomerase I inhibitors), …See details»
Azaya Therapeutics, Inc. | Insights
Mar 19, 2012 Latest on Azaya Therapeutics, Inc. Already A Biomedtracker Subscriber? You have access to the full company record through your subscription. Go To Biomedtracker. …See details»
Cytori to Acquire Proprietary Nanoparticle Development
Jan 19, 2017 About Azaya Therapeutics Azaya Therapeutics, Inc. is an oncology company focused on developing more effective cancer treatments through its novel nanotechnology …See details»
Azaya Therapeutics and its nanoparticle cancer drugs acquired by …
Feb 16, 2017 Cytori Therapeutics (NSDQ:CYTX) said yesterday that it completed its acquisition of San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs.. In late January, …See details»
Cytori to add cancer drugs, nanoparticle tech in Azaya deal
Jan 20, 2017 Cytori Therapeutics is set to gain cancer drugs and a liposomal nanoparticle technology platform through the acquisition of Azaya Therapeutics. The lead drug is a …See details»
Azaya Therapeutics Patents Nanotherapy Breakthrough
Azaya Therapeutics, Inc., a company developing technology for targeted, safer and more effective chemotherapy drugs, has been granted a patent from the U.S. Patent and Trademark Office …See details»
Cytori Completes Acquisition of Azaya Therapeutics Assets,
SAN DIEGO, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) today announced it has completed its acquisition of assets of...See details»
Azaya licenses new technology for head and neck cancer treatment
Michael Dwyer, president and CEO of Azaya Therapeutics, said: “Licensing this technology from UTHSCSA adds a very promising new asset to Azaya’s product portfolio. This treatment …See details»
Working at Azaya Therapeutics - Glassdoor
See what employees say it's like to work at Azaya Therapeutics. Salaries, reviews, and more - all posted by employees working at Azaya Therapeutics. Skip to ... from the bottom up. The …See details»
Azaya Therapeutics licenses promising treatment for head and …
Azaya Therapeutics, Inc., announced that it has signed a licensing agreement to further develop a breakthrough technology that uses liposomes to deliver radiation through direct injection into …See details»
Pharmacokinetic study of ATI-1123 (docetaxel) Azaya Therapeutics ...
May 1, 2007 Abstract. 1509 Background: Docetaxel is a semi-synthetic taxane analog commonly used in the treatment of non-small cell lung, prostate, and breast cancer. Docetaxel is poorly …See details»
Azaya Therapeutics Receives FDA Authorization to Start Phase I …
Dec 11, 2009 Azaya Therapeutics, Inc. announced that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product “ATI-1123,” a …See details»